Glaukos (NYSE:GKOS) Stock Moved Up to Strong-Buy by Zacks Research

Glaukos (NYSE:GKOS) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

GKOS has been the subject of a number of other research reports. UBS Group began coverage on shares of Glaukos in a report on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 price objective for the company. Piper Sandler reissued an “overweight” rating and set a $240.00 target price (up from $195.00) on shares of Glaukos in a report on Thursday. JPMorgan Chase & Co. raised their price target on shares of Glaukos from $200.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday. Wells Fargo & Company lifted their price target on shares of Glaukos from $178.00 to $226.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Needham & Company LLC lifted their price target on shares of Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $216.71.

Glaukos Price Performance

NYSE GKOS opened at $240.81 on Wednesday. Glaukos has a fifty-two week low of $80.90 and a fifty-two week high of $243.71. The business has a fifty day moving average of $172.26 and a 200-day moving average of $140.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative return on equity of 0.98% and a negative net margin of 24.60%. The firm’s revenue for the quarter was up 58.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) earnings per share. Equities research analysts predict that Glaukos will post -0.32 earnings per share for the current year.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 60,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 82,500 shares of company stock worth $14,862,000 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Glaukos in the second quarter valued at approximately $1,333,318,000. Jupiter Topco LLC bought a new stake in Glaukos during the 2nd quarter worth approximately $679,614,000. Primecap Management Co. CA acquired a new position in Glaukos in the 2nd quarter valued at approximately $424,969,000. Janus Henderson Group PLC increased its position in Glaukos by 77.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after acquiring an additional 2,329,608 shares during the period. Finally, William Blair Investment Management LLC bought a new position in shares of Glaukos during the second quarter valued at $92,476,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Q3 results far exceeded expectations: Third-quarter revenue rose 58% year over year to approximately $211 million, well above the roughly $168 million analyst estimate. The company reported adjusted EPS of $0.47 versus consensus expectations for a loss of about $0.10–$0.12, compared with a $0.16 loss a year earlier. Glaukos Stock Charges Higher on Q3 Earnings Surprise
• Positive Sentiment: Profitability improved: Glaukos reported approximately $2 million in GAAP net income, or $0.03 per diluted share, marking a swing from a year-earlier loss. Operating cash flow was $14.8 million, and the company ended the quarter with $162.3 million in cash. Glaukos Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Sales outlook was raised: Management increased its 2026 revenue guidance to $775 million–$785 million from $680 million–$700 million and introduced a preliminary 2027 sales target of $1 billion. Investors viewed the outlook as evidence that iDose TR and Epioxa can sustain strong growth. Glaukos Sets $1 Billion 2027 Sales Goal
• Positive Sentiment: Analysts raised targets: JPMorgan lifted its target to $240 and retained an Overweight rating, while Needham raised its target to $251 with a Buy rating. BTIG, Stifel and Wells Fargo also increased their targets and maintained positive ratings. JPMorgan Analyst Recommendation
• Neutral Sentiment: Valuation has become demanding: The stock was trading near its 52-week high and above several newly raised analyst targets, including those from Wells Fargo, BTIG and Stifel, potentially limiting near-term upside despite bullish ratings.
• Negative Sentiment: Insider selling remains a risk signal: Data provided shows 32 open-market insider sales and no purchases over the past six months. The company also remains dependent on continued execution to meet its ambitious 2027 target.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.